Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

ResMed’s (RMD) Sleep Business Booms Even As One Product Stumbles

ResMed’s (RMD) Sleep Business Booms Even As One Product Stumbles

ResMed reported a strong fourth-quarter and full fiscal year for fiscal 2026, with revenue rising 9% and 10% respectively, to $1.5 billion and $1.67 billion. Non-GAAP earnings per share increased 16% to $2.95. The company's core sleep apnea business continues to grow, with data showing patients prescribed both a GLP-1 drug and PAP therapy are 11% more likely to start PAP therapy than those with a PAP script alone.

Over 40% of patients had started PAP at 90 days after diagnosis, compared to under 3% on GLP-1. ResMed has partnered with wearable maker Oura, sending roughly 13,000 users to its sleep assessment, three-quarters of whom were previously undiagnosed. The company expanded the AirSense 11 platform into China and launched new AirCurve 11 bilevel devices in several markets.

New fabric masks, like the AirTouch N30i, are also driving higher patient compliance. However, life support device revenue fell significantly due to suspension of new Astral sales, with a $42 million provision booked. Free cash flow fell 21% year over year to $404 million, while operating margin slipped and R&D spending increased.

Guided fiscal 2027 EPS growth is expected to be 7% to 10%, lower than the 16% non-GAAP growth recently posted. ResMed's dividend was raised 10% to $0.66 per share, and the company plans to return over $1.85 billion to shareholders in fiscal 2027. Despite a high short interest, the stock trades at a modest forward P/E of 18.69.

Written by urgent.news from Yahoo Finance's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at finance.yahoo.com →

More in Finance & Markets

More from Monday 17 August →